Abstract
IntroductionThe strategy for initiating antithrombotic therapy to prevent bioprosthetic valve thrombosis (BPVT) after transcatheter aortic valve replacement (TAVR) remains uncertain. There is still lacking evidence on the efficacy and safety...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have